These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3824531)

  • 1. Prognostic factors in advanced metastatic and recurrent melanoma treated with DTIC.
    Pawlicki M; Skołyszewski J; Stryjewska B; Nosek H
    Tumori; 1987 Feb; 73(1):49-50. PubMed ID: 3824531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dacarbazine (DTIC) in malignant melanoma: reduced toxicity with protection from light.
    Koriech OM; Shükla VS
    Clin Radiol; 1981 Jan; 32(1):53-5. PubMed ID: 7214822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
    Van Dyk JJ; Falkson G
    Med Pediatr Oncol; 1975; 1(2):107-11. PubMed ID: 1228411
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hypersensitivity to dacarbazine in patients with metastatic malignant melanoma].
    Levy A; Guitera P; Kerob D; Ollivaud L; Archimbaud A; Dubertret L; Basset-Seguin N
    Ann Dermatol Venereol; 2006 Feb; 133(2):157-60. PubMed ID: 16508601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Experience with interferon alpha 2b combined with dacarbazine in the treatment of metastatic malignant melanoma.
    Falkson CI
    Med Oncol; 1995 Mar; 12(1):35-40. PubMed ID: 8542245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of temozolomide on central nervous system relapse in patients with advanced melanoma.
    Paul MJ; Summers Y; Calvert AH; Rustin G; Brampton MH; Thatcher N; Middleton MR
    Melanoma Res; 2002 Apr; 12(2):175-8. PubMed ID: 11930115
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC.
    Busch C; Geisler J; Lillehaug JR; Lønning PE
    Eur J Cancer; 2010 Jul; 46(11):2127-33. PubMed ID: 20541396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment with pegylated interferon-alpha-2a and dacarbazine in patients with advanced metastatic melanoma: a phase 2 study.
    Hauschild A; Dummer R; Ugurel S; Kaehler KC; Egberts F; Fink W; Both-Skalsky J; Laetsch B; Schadendorf D
    Cancer; 2008 Sep; 113(6):1404-11. PubMed ID: 18615619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Results with methyl-CCNU and DTIC in metastatic melanoma.
    Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
    Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunochemotherapy with recombinant interferon-alpha 2b plus dacarbazine in the treatment of advanced malignant melanoma.
    Strojan P; Rudolf Z
    Melanoma Res; 1997 Oct; 7(5):420-7. PubMed ID: 9429226
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma.
    Middleton MR; Grob JJ; Aaronson N; Fierlbeck G; Tilgen W; Seiter S; Gore M; Aamdal S; Cebon J; Coates A; Dreno B; Henz M; Schadendorf D; Kapp A; Weiss J; Fraass U; Statkevich P; Muller M; Thatcher N
    J Clin Oncol; 2000 Jan; 18(1):158-66. PubMed ID: 10623706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolated limb perfusion for stage I melanoma of the extremity: a comparison of melphalan and dacarbazine (DTIC).
    Edwards MJ; Boddie AW; Ames FC; McBride CM
    South Med J; 1989 Aug; 82(8):985-7, 989. PubMed ID: 2762904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of melanoma recurring as subcutaneous metastatic melanoma with overlying ecchymoses.
    Dehart WK; Gilliam AC; Lu KQ; Brell J
    Arch Dermatol; 2008 Apr; 144(4):561-2. PubMed ID: 18427064
    [No Abstract]   [Full Text] [Related]  

  • 15. In-vitro and in-vivo inhibition of melanoma growth and metastasis by the drug combination of celecoxib and dacarbazine.
    Sadhu SS; Wang S; Averineni RK; Seefeldt T; Yang Y; Guan X
    Melanoma Res; 2016 Dec; 26(6):572-579. PubMed ID: 27540834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
    Serrone L; Zeuli M; Sega FM; Cognetti F
    J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma.
    Birkeland E; Busch C; Berge EO; Geisler J; Jönsson G; Lillehaug JR; Knappskog S; Lønning PE
    Clin Exp Metastasis; 2013 Oct; 30(7):867-76. PubMed ID: 23673558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DTIC vs. IFN-alpha plus DTIC in the treatment of patients with metastatic malignant melanoma.
    Rudolf Z; Strojan P
    Neoplasma; 1996; 43(2):93-7. PubMed ID: 8843969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma.
    Schadendorf D; Worm M; Czarnetzki BM
    J Neurooncol; 1993 Apr; 16(1):77-9. PubMed ID: 8410146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Photosensitization with DTIC therapy in metastatic malignant melanoma].
    Bolling R; Meyer-Hamme S; Schauder S
    Hautarzt; 1980 Nov; 31(11):602-5. PubMed ID: 7451142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.